Targeting Metabolic Vulnerabilities of Triple Negative Breast Cancer: Vignesh Gunasekharan, PhD, Associate Research Scientist, Medical Oncology
DEOXYMAB: A Targeted Biologic that is Synthetically Lethal to Triple Negative Breast Cancer Brain Metastases: James Hansen, MD, MS, Associate Professor of Therapeutic Radiology and a member of Yale Cancer Center's Radiobiology and Radiotherapy Research Program
Feasibility of Expansion and Characterization of Tumor Infiltrating Lymphocytes (TILs) from Breast Cancer: Tristen Park, MD, Assistant Professor of Surgery (Oncology) and a member of Yale Cancer Center's Cancer Immunology Research Program
Submitted by Vignesh Gunasekharan on July 26, 2019